Loading...

Episurf Medical

DB:16E
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
16E
DB
SEK52M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in the Nordic countries, Benelux, Germany, and the United Kingdom. The last earnings update was 35 days ago. More info.


Add to Portfolio Compare Print
  • Episurf Medical has significant price volatility in the past 3 months.
16E Share Price and Events
7 Day Returns
-15.6%
DB:16E
1.2%
DE Medical Equipment
-0%
DE Market
1 Year Returns
-
DB:16E
12.7%
DE Medical Equipment
-11.5%
DE Market
16E Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Episurf Medical (16E) -15.6% -15.6% -56.4% - - -
DE Medical Equipment 1.2% 2% 4.4% 12.7% 102.6% 232.2%
DE Market -0% -3.3% 2.1% -11.5% 8.9% 8.1%
1 Year Return vs Industry and Market
  • No trading data on 16E.
  • No trading data on 16E.
Price Volatility
16E
Industry
5yr Volatility vs Market

Value

 Is Episurf Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Episurf Medical. This is due to cash flow or dividend data being unavailable. The share price is €0.13.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Episurf Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Episurf Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:16E PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in SEK SEK-1.85
OM:EPIS B Share Price ** OM (2019-05-22) in SEK SEK1.49
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 35.61x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 20.26x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Episurf Medical.

DB:16E PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:EPIS B Share Price ÷ EPS (both in SEK)

= 1.49 ÷ -1.85

-0.81x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Episurf Medical is loss making, we can't compare its value to the DE Medical Equipment industry average.
  • Episurf Medical is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Episurf Medical's expected growth come at a high price?
Raw Data
DB:16E PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.81x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
9.3%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 3.1x
Germany Market PEG Ratio Median Figure of 271 Publicly-Listed Companies 1.49x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Episurf Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Episurf Medical's assets?
Raw Data
DB:16E PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in SEK SEK0.87
OM:EPIS B Share Price * OM (2019-05-22) in SEK SEK1.49
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.17x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.78x
DB:16E PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:EPIS B Share Price ÷ Book Value per Share (both in SEK)

= 1.49 ÷ 0.87

1.71x

* Primary Listing of Episurf Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Episurf Medical is good value based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Episurf Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Episurf Medical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Episurf Medical expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Episurf Medical expected to grow at an attractive rate?
  • Unable to compare Episurf Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Episurf Medical's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Episurf Medical's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:16E Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:16E Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 9.3%
DB:16E Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 50.7%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:16E Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:16E Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 56 1
2021-12-31 32 -46 -51 3
2020-12-31 20 -57 -62 3
2019-12-31 11 -66 -69 3
DB:16E Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-03-31 4 -54 -59
2018-12-31 4 -52 -58
2018-09-30 4 -49 -58
2018-06-30 3 -51 -59
2018-03-31 3 -62 -55
2017-12-31 3 -61 -61
2017-09-30 3 -59 -64
2017-06-30 2 -59 -65
2017-03-31 2 -53 -69
2016-12-31 2 -56 -62
2016-09-30 7 -55 -57
2016-06-30 8 -50 -53

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Episurf Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Episurf Medical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:16E Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Episurf Medical Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:16E Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 -1.00 -1.00 -1.00 1.00
2021-12-31 -1.60 -1.23 -2.16 3.00
2020-12-31 -1.92 -1.62 -2.31 3.00
2019-12-31 -2.12 -1.91 -2.32 3.00
DB:16E Past Financials Data
Date (Data in SEK Millions) EPS *
2019-03-31 -1.85
2018-12-31 -1.87
2018-09-30 -1.90
2018-06-30 -1.92
2018-03-31 -1.81
2017-12-31 -2.18
2017-09-30 -2.54
2017-06-30 -2.76
2017-03-31 -3.44
2016-12-31 -3.24
2016-09-30 -3.14
2016-06-30 -3.23

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Episurf Medical will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Episurf Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Episurf Medical has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Episurf Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Episurf Medical's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Episurf Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Episurf Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Episurf Medical's 1-year growth to the DE Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Episurf Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Episurf Medical Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:16E Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 4.40 -59.10 26.40
2018-12-31 4.00 -57.80 27.30
2018-09-30 3.70 -58.00 28.50
2018-06-30 3.20 -58.70 30.70
2018-03-31 3.00 -55.40 30.60
2017-12-31 2.50 -61.10 33.30
2017-09-30 2.61 -64.05 33.50
2017-06-30 1.68 -65.50 32.51
2017-03-31 1.93 -68.97 31.88
2016-12-31 2.41 -61.67 28.34
2016-09-30 7.37 -57.36 29.94
2016-06-30 7.95 -53.23 30.99
2016-03-31 7.36 -48.14 30.40
2015-12-31 6.61 -43.97 26.83
2015-09-30 1.70 -37.88 20.95
2015-06-30 2.27 -34.27 18.04
2015-03-31 2.12 -32.21 14.01
2014-12-31 2.35 -32.91 12.54
2014-09-30 2.99 -31.00 10.55
2014-06-30 2.27 -28.48 7.66
2014-03-31 2.16 -25.76 7.49
2013-12-31 1.70 -22.86 6.92
2013-09-30 -22.63 -1.05
2013-06-30 -20.59 0.43
2013-03-31 -17.40 1.74
2012-12-31 -15.77 4.16
2012-09-30 -12.96 13.43
2012-06-30 -12.90 12.98

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Episurf Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Episurf Medical has efficiently used its assets last year compared to the DE Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Episurf Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Episurf Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Episurf Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Episurf Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Episurf Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Episurf Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Episurf Medical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Episurf Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Episurf Medical Company Filings, last reported 1 month ago.

DB:16E Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 30.60 9.70 13.50
2018-12-31 44.80 2.80 28.30
2018-09-30 46.10 4.30 29.90
2018-06-30 57.30 0.00 44.90
2018-03-31 72.10 0.00 56.80
2017-12-31 85.60 0.00 71.30
2017-09-30 101.05 0.00 87.54
2017-06-30 114.44 0.00 103.14
2017-03-31 128.25 0.00 127.32
2016-12-31 48.70 0.00 42.30
2016-09-30 67.31 0.00 56.13
2016-06-30 82.38 0.00 71.59
2016-03-31 98.29 0.00 88.79
2015-12-31 109.93 0.00 103.96
2015-09-30 124.10 0.00 117.80
2015-06-30 20.53 0.00 14.51
2015-03-31 31.32 0.00 25.59
2014-12-31 38.85 0.00 34.49
2014-09-30 46.90 0.00 41.40
2014-06-30 54.21 0.00 51.29
2014-03-31 63.53 0.00 59.44
2013-12-31 71.61 0.00 68.87
2013-09-30 77.76 0.00 75.62
2013-06-30 63.65 0.00 67.55
2013-03-31 19.06 0.00 17.87
2012-12-31 24.39 0.00 23.08
2012-09-30 30.31 0.00 28.86
2012-06-30 33.04 0.00 32.02
  • Episurf Medical's level of debt (31.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 31.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Episurf Medical has less than a year of cash runway based on current free cash flow.
  • Episurf Medical has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.4% each year.
X
Financial health checks
We assess Episurf Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Episurf Medical has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Episurf Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Episurf Medical dividends.
If you bought €2,000 of Episurf Medical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Episurf Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Episurf Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:16E Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:16E Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Episurf Medical has not reported any payouts.
  • Unable to verify if Episurf Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Episurf Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Episurf Medical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Episurf Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Episurf Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Episurf Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Episurf Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Pål Ryfors
COMPENSATION SEK2,200,000
AGE 35
TENURE AS CEO 1.9 years
CEO Bio

Mr. Pal Ryfors has been the Chief Executive Officer of Episurf Medical AB since June 2, 2017 and as its Chief Financial Officer since December 14, 2015. Mr. Ryfors served as an Acting Chief Executive Officer of Episurf Medical AB from January 5, 2017 to June 2, 2017. Mr. Ryfors has vast experience from leading positions within the finance and banking sector both in the Nordic and internationally. He served as the Chief Financial Officer at Marginalen Bank Bankaktiebolag since joining in November 2012. He was responsible for the strategic financial planning and management, as well as leading the financial operations and implementing corporate development initiatives. He served as Head of Group Controlling at Hoist Finance. He served with investment banking at Société Générale in London and at Kaupthing Bank in Stockholm. He served as an investment banker at Societe Generale, where he joined after holding several leading positions in the restructuring of the Swedish operations of Kaupthing Bank. He has been Director at Doxa AB (publ) since 2018. He has a Bachelor in Financial Economics from Gothenburg School of Economics.

CEO Compensation
  • Pål's compensation has increased whilst company is loss making.
  • Pål's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Episurf Medical management team in years:

2.1
Average Tenure
43
Average Age
  • The tenure for the Episurf Medical management team is about average.
Management Team

Pål Ryfors

TITLE
Chief Executive Officer
COMPENSATION
SEK2M
AGE
35
TENURE
1.9 yrs

Veronica Wallin

TITLE
Chief Financial Officer
AGE
32
TENURE
1.9 yrs

Jeanette Spångberg

TITLE
Chief Operating Officer
AGE
45
TENURE
8.3 yrs

Göran Martinsson

TITLE
Sales Director
AGE
59
TENURE
5.3 yrs

Fredrik Zetterberg

TITLE
Marketing Director
AGE
43
TENURE
2.3 yrs

Katarina Flodstrom

TITLE
Chief Regulatory Officer of Quality Affairs & Intellectual Property
AGE
43
TENURE
0.9 yrs

Beata Lihammar

TITLE
Principal Auditor
Board of Directors Tenure

Average tenure and age of the Episurf Medical board of directors in years:

3
Average Tenure
60
Average Age
  • The tenure for the Episurf Medical board of directors is about average.
Board of Directors

Dennis Stripe

TITLE
Chairman
COMPENSATION
SEK400K
AGE
61
TENURE
2.8 yrs

Leif Ryd

TITLE
Chairman of Clinical Advisory Board
COMPENSATION
SEK700K
AGE
69

Tim Spalding

TITLE
Member of Clinical Advisory Board
TENURE
3.5 yrs

Johannes Holz

TITLE
Member of Clinical Advisory Board
TENURE
3.5 yrs

Mats Brittberg

TITLE
Member of Clinical Advisory Board
TENURE
3.5 yrs

Karl Eriksson

TITLE
Member of Clinical Advisory Board
TENURE
3.5 yrs

Christian Krüeger

TITLE
Director
COMPENSATION
SEK100K
AGE
52
TENURE
3 yrs

Wilder Fulford

TITLE
Director
COMPENSATION
SEK200K
AGE
60
TENURE
3 yrs

Adam Mitchell

TITLE
Member of Clinical Advisory Board
TENURE
2.3 yrs

Laura Shunk

TITLE
Director
COMPENSATION
SEK200K
AGE
60
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
27. Dec 18 Buy Laura Shunk Individual 19. Dec 18 19. Dec 18 10,000 €0.03 €338
17. Dec 18 Buy Leif Ryd Individual 17. Dec 18 17. Dec 18 25,000 €0.29 €7,195
06. Dec 18 Buy Göran Martinsson Individual 05. Dec 18 05. Dec 18 10,000 €0.29 €2,886
16. Nov 18 Buy Veronica Wallin Individual 14. Nov 18 14. Nov 18 20,000 €0.47 €9,336
16. Nov 18 Buy Göran Martinsson Individual 04. Nov 18 16. Nov 18 33,000 €0.46 €15,052
16. Nov 18 Buy Laura Shunk Individual 14. Nov 18 14. Nov 18 20,000 €0.47 €9,336
13. Nov 18 Buy Leif Ryd Individual 12. Nov 18 12. Nov 18 11,000 €0.45 €4,960
X
Management checks
We assess Episurf Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Episurf Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in the Nordic countries, Benelux, Germany, and the United Kingdom. The company offers Episealer Condyle Solo for the treatment of localized cartilage and underlying bone defects on the femoral condyles of the knee joint; Episealer Trochlea Solo to treat localized cartilage and underlying bone defects in the area behind the patella; and Episealer Femoral Twin for treating elongated localized cartilage and underlying bone defects on the femoral condyles and in the trochlea area of the knee joint. It also provides Epiguide MOS, a surgical drill guide, which is designed for use in mosaicplasty surgery for treatment of cartilage and deep underlying bone defects in the knee joint. In addition, the company offers µiFidelity system for damage assessment, surgical pre-planning, and patient customization of implants and related surgical instruments; and Epioscopy, a damage assessment tool. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was founded in 2008 and is headquartered in Stockholm, Sweden.

Details
Name: Episurf Medical AB (publ)
16E
Exchange: DB
Founded: 2008
SEK4,866,236
35,113,686
Website: http://www.episurf.com
Address: Episurf Medical AB (publ)
Karlavägen 60,
Stockholm,
Stockholm County, 114 49,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM EPIS B Class B Shares OMX Nordic Exchange Stockholm SE SEK 05. Nov 2010
DB 16E Class B Shares Deutsche Boerse AG DE EUR 05. Nov 2010
LSE 0QUT Class B Shares London Stock Exchange GB SEK 05. Nov 2010
OM EPIS BTA B SHS OMX Nordic Exchange Stockholm SE SEK 15. May 2019
Number of employees
Current staff
Staff numbers
25
Episurf Medical employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 01:19
End of day share price update: 2019/05/22 00:00
Last estimates confirmation: 2019/05/02
Last earnings filing: 2019/04/18
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.